• S3:E6 – Heart Failure Morning Commute: Decisions in the Management of Heart Failure
    Mar 28 2022

    When should heart failure therapies be combined, switched, or stopped? Our faculty discuss this topic as well as how Covid-19 has impacted heart failure treatment. 

    Visit www.morningcommutepodcast.com/heartfailure6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

    Show more Show less
    25 mins
  • S3:E5 – Heart Failure Morning Commute: More Heart Failure Drugs, More Choices
    Mar 1 2022

    With the many therapies that are now available for the treatment of heart failure, who are the best candidates for these medications and what are the potential side effects? Our faculty discuss this and more.

    Visit www.morningcommutepodcast.com/heartfailure5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

    Show more Show less
    21 mins
  • S3:E4 – Heart Failure Morning Commute: Managing Heart Failure in Patients With Type 2 Diabetes
    Mar 1 2022

    In this podcast our faculty discuss treating patients who have diabetes and heart failure and the remarkable story of SGLT-2 inhibitors for this patient population.  

    Visit www.morningcommutepodcast.com/heartfailure4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

    Show more Show less
    22 mins
  • S3:E3 – Heart Failure Morning Commute: Preventing Heart Failure in High-Risk Patients With Type 2 Diabetes
    Feb 28 2022

    How should the patient with diabetes who is at risk of developing heart failure be managed? What medication is needed and how important is prevention through diet and exercise?

    Visit www.morningcommutepodcast.com/heartfailure3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

    Show more Show less
    21 mins
  • S3:E2 – Heart Failure Morning Commute: Managing Patients With Mid-Range or Preserved EF
    Feb 28 2022

    What are the current guidelines for managing patients with heart failure and why are heart failure labels so confusing? Our faculty help decipher these and more in this podcast episode.

    Visit www.morningcommutepodcast.com/heartfailure2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

    Show more Show less
    21 mins
  • S3:E1 – Heart Failure Morning Commute: Patient Diagnosis and Subtype Classification of Heart Failure
    Feb 28 2022

    In this podcast our faculty discuss diagnosing the heart failure patient in the primary care setting. What should the process be for making this diagnosis and how important is taking a complete medical and family history?

    Visit www.morningcommutepodcast.com/heartfailure1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

    Show more Show less
    24 mins
  • S2:E3 – SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action
    Mar 30 2021

    Visit http://morningcommutepodcast.com/SGLT2inhibitors6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. James Januzzi and Dr. Silvio Inzucchi discuss the surge in collaboration between primary care physicians, endocrinologists, and cardiologists and the groundswell of cardiometabolic clinics. They attribute this to cardiologists moving beyond the so-called glucocentric view and focusing on how diabetes therapies might help reduce cardiovascular risk as well. Drs. Januzzi and Inzucchi will also discuss the recent guidelines that now incorporate sodium-glucose cotransporter 2 (SGLT-2) inhibitors into clinical pathways.

    Show more Show less
    24 mins
  • S2:E2 – SGLT-2 Inhibitors Morning Commute: The Heart Failure Connection
    Mar 30 2021

    Visit http://morningcommutepodcast.com/SGLT2inhibitors5 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi discuss how sodium-glucose cotransporter 2 (SGLT-2) inhibitors evolved from treatments for type 2 diabetes mellitus (T2DM) to key treatments for patients with heart failure. Drs. Januzzi and Inzucchi look at the pivotal trials that thrust these treatments into the heart failure treatment limelight.

    Show more Show less
    24 mins